ProCE Banner Activity

Shared Decision-Making and the Current Landscape of Checkpoint Inhibitor Therapy in Metastatic NSCLC

Slideset Download
Download this slideset for expert perspectives on the optimal use of immunotherapy for the treatment of advanced NSCLC in the clinic today, including management of immune-related adverse events and thoughts on involving your patients in treatment decisions.

Released: January 28, 2020

Expiration: January 26, 2021

No longer available for credit.

Share

Faculty

Heather J. Jackson

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Helena Yu

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Heather J. Jackson, PhD, FNP-BC, NEA-BC, FAANP

Associate Professor
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University School of Nursing
Administrative Director of Advanced Practice
Division of Hematology/Oncology
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York